0000000000511237

AUTHOR

Jean Paul Pais De Barros

showing 2 related works from this author

Liver X receptor activation promotes polyunsaturated fatty acid synthesis in macrophages : relevance in the context of atherosclerosis

2015

Objective— Liver X receptors (LXRs) modulate cholesterol and fatty acid homeostasis as well as inflammation. This study aims to decipher the role of LXRs in the regulation of polyunsaturated fatty acid (PUFA) synthesis in macrophages in the context of atherosclerosis. Approach and Results— Transcriptomic analysis in human monocytes and macrophages was used to identify putative LXR target genes among enzymes involved in PUFA biosynthesis. In parallel, the consequences of LXR activation or LXR invalidation on PUFA synthesis and distribution were determined. Finally, we investigated the impact of LXR activation on PUFA metabolism in vivo in apolipoprotein E–deficient mice. mRNA levels of acyl…

Context (language use)Biologydigestive systemchemistry.chemical_compoundMicearachidonic acidAnimalsHumansFatty acid homeostasisReceptorLiver X receptor[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyLiver X Receptorschemistry.chemical_classificationCholesterolFatty acidfood and beveragesArteriesAtherosclerosisOrphan Nuclear ReceptorsmacrophagesBiochemistrychemistryn-3 polyunsaturated fatty acidFatty Acids UnsaturatedArachidonic acidlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineSterol Regulatory Element Binding Protein 1Polyunsaturated fatty acidFoam Cellsliver X receptor
researchProduct

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertas…

2021

OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-…

medicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismLipoproteinsAdipose tissue030209 endocrinology & metabolismLipoproteins VLDL03 medical and health sciencesMice0302 clinical medicineInternal medicineInternal MedicinemedicineAnimalsHumans030212 general & internal medicineSubtilisinsAdvanced and Specialized NursingbiologyCatabolismLiraglutidebusiness.industryPCSK9Liraglutidemedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2biology.proteinKexinProprotein Convertase 9businessRetinol-Binding Proteins PlasmaDyslipidemiamedicine.drugLipoprotein
researchProduct